Showing 5591-5600 of 5806 results for "".
- Omalizumab Shown to Significantly Improve Chronic Idiopathic Urticaria Symptomshttps://practicaldermatology.com/news/20130227-omalizumab_shown_to_significantly_improve_chronic_idiopathic_urticaria_symptoms/2459605/Results from the recent ASTERIA II trial showed that the biologic agent omalizumab (Novartis) may be effective for patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite treat
- Epiduo Approved For Patients as Young as 9-Years-Oldhttps://practicaldermatology.com/news/20130219-epiduo_approved_to_treat_acne_in_patients_as_young_as_nine_years_old/2459612/Based on the results of a recent clinical study in pediatric patients, the FDA has approved Epiduo (adapalene 0.1%/BPO 2.5%, Galderma) Gel to treat acne in children as young as nine years old. In the 12-week multicenter, randomized, vehicle-controlled, double-blind study, investigators evaluated the
- Aqua Pharmaceuticals Announces New VP of Saleshttps://practicaldermatology.com/news/20130212-aqua_pharmaceuticals_announces_new_vp_of_sales/2459617/Aqua Pharmaceuticals recently promoted Ted White to Chief Operating Officer (COO). White moves to the new role from his previous position as Vice President of Sales. As COO, White will be responsible for overseeing the daily operation of Aqua and developing business strategies, serving as second-in-
- Tri-Luma Cream Available Againhttps://practicaldermatology.com/news/20130212-tri-luma_cream_available_again/2459616/Galderma Laboratories, L.P. recently announced that Tri-Luma® (fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%) Cream, the only FDA-approved triple combination topical product indicated for the short-term (up to 8 weeks) treatment of moderate to severe melasma of the face, is now avai
- Jan Marini Launches New Peel Systemhttps://practicaldermatology.com/news/20130206-jan_marini_launches_new_peel_system/2459619/Jan Marini Skin Research launched the Marini Peel Systems, which combine peels with concentrated retinol, peptides, and antioxidants for individuals seeking more aggressive treatments for issues ranging from sun damage to skin coloration. The systems include the Refine Peel, for skin rejuvenation, t
- Merz Aesthetics Appoints New VPhttps://practicaldermatology.com/news/20130206-merz_aesthetics_appoints_new_vp/2459620/Jim Hartman has been appointed Vice President of Merz Aesthetics, Inc. Business Unit, which includes Xeomin, Radiesse, and Belotero Balance. Prior to joining Merz, Hartman was the Vice President, Global Marketing & Business Development, at Obagi Medical Products, a provider of topical skincare treat
- La Roche-Posay Contributes to The Mollie Biggane Melanoma Foundationhttps://practicaldermatology.com/news/20130203-la_roche-posay_contributes_to_the_mollie_biggane_melanoma_foundation/2459621/As part of their continued efforts towards sun safety education and awareness, La Roche-Posay is partnering with Mollie's Fund for the second year in a row. To honor the life of Mollie Biggane – a college sophomore who tragically passed away from melanoma a
- AADA Applauds Proposed Legislation to Repeal Medicare's IPABhttps://practicaldermatology.com/news/20130130-aada_applauds_proposed_legislation_to_repeal_medicares_ipab/2459624/The American Academy of Dermatology Association (AADA) issued a statement applauding the introduction of the Protecting Seniors' Access to Medicare Act, legislation that would repeal the Independent Payment Advisory Board (IPAB) created by the 2010 Affordable Care Act. The AADA argues that the IPAB
- Study: Most Skin-Cancer Apps Unreliablehttps://practicaldermatology.com/news/20130123-study_most_skin-cancer_apps_unreliable/2459630/The University of Pittsburgh studied four smartphone apps that evaluate melanoma by analyzing images submitted by the users. One app works by having a board-certified dermatologist look at the photos, while the other three apps analyze the images by computer algorithm. The best-performing of the com
- Provectus Pharmaceuticals to Present on PV-10 at AACRhttps://practicaldermatology.com/news/20130123-provectus_pharmaceuticals_to_present_on_pv-10_at_aacr/2459631/Provectus Pharmaceuticals, Inc. will present data on PV-10 in a poster presentation at the American Association for Cancer Research Annual Meeting in Washington, DC. The PV-10 combination therapy poster, based upon an abstract entitled "Combination o